Open AccessPerformance of Validated MicroRNA Biomarkers for Alzheimer’s Disease in Mild Cognitive Impairment
Author(s) -
Ursula S. Sandau,
Jack Wiedrick,
Sierra J. Smith,
Trevor J. McFarland,
Theresa A. Lusardi,
Babett Lind,
Christina A. Harrington,
Jodi Lapidus,
Douglas Galasko,
Joseph F. Quinn,
Julie A. Saugstad
Publication year - 2020
Publication title -
journal of alzheimer's disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.677
H-Index - 139
eISSN - 1875-8908
pISSN - 1387-2877
DOI - 10.3233/jad-200396
Subject(s) - microrna , biomarker , medicine , apolipoprotein e , oncology , area under the curve , diagnostic biomarker , cognitive impairment , disease , alzheimer's disease , stage (stratigraphy) , alzheimer's disease neuroimaging initiative , bioinformatics , diagnostic accuracy , biology , genetics , gene , paleontology
Cerebrospinal fluid (CSF) microRNA (miRNA) biomarkers of Alzheimer's disease (AD) have been identified, but have not been evaluated in prodromal AD, including mild cognitive impairment (MCI).